Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Faron Pharmaceuticals Oy ( (GB:FARN) ) is now available.
Faron Pharmaceuticals Ltd has approved the exercise of 517,795 special rights, resulting in the issuance of 517,795 new shares at a subscription price of EUR 965,998.35. This move is part of the company’s strategy to manage its convertible bond arrangement with Heights Capital Management by converting debt into equity. The newly issued shares will be registered in the Finnish Trade Register and are expected to commence trading on Nasdaq First North Growth Market Finland and AIM on or around December 5, 2025. This development increases the total number of voting rights in the company, impacting shareholder calculations and potentially enhancing Faron’s financial flexibility.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Its lead asset, bexmarilimab, is a novel anti-Clever-1 humanized antibody aimed at removing cancer immunosuppression by reprogramming myeloid cell function. Bexmarilimab is currently in Phase I/II clinical trials for potential use in combination with standard treatments for hematological cancers.
Learn more about FARN stock on TipRanks’ Stock Analysis page.